Trial Profile
Real world effectiveness, adherence, and treatment discontinuation in patient with hepatitis C virus (HCV) treated with Ledipasvir/sofosbuvir.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2017
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck & Co
- 06 Oct 2017 New trial record
- 01 Sep 2017 Results assessing real world effectiveness, adherence, and treatment discontinuation in patient with hepatitis C virus (HCV) treated with Ledipasvir/sofosbuvir, were published in the Infectious Diseases and Therapy.